The Nursing and Midwifery Council (NMC) is reviewing its position on remote prescribing of injectable cosmetic products including botulinum toxin, weight loss injections and hyaluronidase.1
Sam Foster, executive nurse director of professional practice at the NMC, has shared that the association’s current position on remote prescribing in aesthetics is that it is unlikely to be suitable for injectable cosmetics. Whilst it recognises there can be many benefits to remote prescribing (including improved access to vital medication for service users, reduced waiting times and better use of resources), the association instead recommends face-to-face consultations, and is looking at making this a clear requirement.
This is because most non-surgical aesthetic procedures take place in the private sector, with limited access to patients’ NHS medical records. The NMC feels that limited access to medical records combined with the lack of face-to-face consultation limits prescribers’ ability to undertake appropriate clinical assessment; therefore, avoiding remote prescribing is thought…
